SOPH SOPHiA Genetics SA

  1. Stocks
  2. Healthcare
  3. NASDAQ: SOPH

Price (delayed)

$5

Market cap

$326.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.22

Enterprise value

$221.5M

sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and ...

Highlights
SOPH's gross profit is up by 37% year-on-year and by 6% since the previous quarter
SOPHiA Genetics's revenue has increased by 31% YoY and by 6% QoQ
The net income has contracted by 15% from the previous quarter but it has grown by 10% YoY
SOPHiA Genetics's EPS has decreased by 15% from the previous quarter but it has increased by 10% YoY
The company's quick ratio fell by 44% YoY and by 22% QoQ
SOPH's equity is down by 24% year-on-year and by 4.4% since the previous quarter
Sector: Healthcare
Industry: Health Information Services
Peers: PGY PHR PHUN

Key stats

What are the main financial stats of SOPH
Market
Shares outstanding
65.23M
Market cap
$326.15M
Enterprise value
$221.5M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.15
Price to sales (P/S)
5.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.55
Earnings
Revenue
$62.37M
EBIT
-$82.45M
EBITDA
-$74.12M
Free cash flow
-$50.07M
Per share
EPS
-$1.22
Free cash flow per share
-$0.77
Book value per share
$2.33
Revenue per share
$0.96
TBVPS
$2.75
Balance sheet
Total assets
$206.16M
Total liabilities
$54.71M
Debt
$18.6M
Equity
$151.44M
Working capital
$112.43M
Liquidity
Debt to equity
0.12
Current ratio
4.16
Quick ratio
3.84
Net debt/EBITDA
1.41
Margins
EBITDA margin
-118.8%
Gross margin
68.8%
Net margin
-126.6%
Operating margin
-120%
Efficiency
Return on assets
-36.4%
Return on equity
-47.4%
Return on invested capital
-211.1%
Return on capital employed
-48.4%
Return on sales
-132.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SOPH stock price

How has the SOPHiA Genetics stock price performed over time
Intraday
-1.57%
1 week
-0.6%
1 month
-2.91%
1 year
8.46%
YTD
6.16%
QTD
1.42%

Financial performance

How have SOPHiA Genetics's revenue and profit performed over time
Revenue
$62.37M
Gross profit
$42.91M
Operating income
-$74.83M
Net income
-$78.98M
Gross margin
68.8%
Net margin
-126.6%
SOPH's gross profit is up by 37% year-on-year and by 6% since the previous quarter
The operating margin has grown by 35% YoY
SOPHiA Genetics's revenue has increased by 31% YoY and by 6% QoQ
SOPHiA Genetics's net margin has increased by 31% YoY but it has decreased by 8% QoQ

Growth

What is SOPHiA Genetics's growth rate over time

Valuation

What is SOPHiA Genetics stock price valuation
P/E
N/A
P/B
2.15
P/S
5.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.55
SOPHiA Genetics's EPS has decreased by 15% from the previous quarter but it has increased by 10% YoY
The P/B is 34% more than the last 4 quarters average of 1.6
SOPH's equity is down by 24% year-on-year and by 4.4% since the previous quarter
SOPHiA Genetics's revenue has increased by 31% YoY and by 6% QoQ
The P/S is 9% above the last 4 quarters average of 4.8

Efficiency

How efficient is SOPHiA Genetics business performance
The ROIC has plunged by 57% YoY and by 26% from the previous quarter
SOPHiA Genetics's ROS has increased by 29% YoY but it has decreased by 9% from the previous quarter
SOPHiA Genetics's ROE has decreased by 23% from the previous quarter and by 20% YoY
The ROA has declined by 19% since the previous quarter and by 11% year-on-year

Dividends

What is SOPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SOPH.

Financial health

How did SOPHiA Genetics financials performed over time
The company's quick ratio fell by 44% YoY and by 22% QoQ
The current ratio has declined by 43% year-on-year and by 22% since the previous quarter
SOPHiA Genetics's debt is 88% lower than its equity
The debt to equity has soared by 50% year-on-year and by 9% since the previous quarter
SOPH's equity is down by 24% year-on-year and by 4.4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.